StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
8217.HK$0.20-2.91%
Fair $0.20+0.0%

8217.HK

Ju Fu Tang Biotech Holdings Co., Ltd

Industrials / Engineering & ConstructionHKSE

$0.20

-0.01 (-2.91%)

Fairly Valued+0.0%Fair Value $0.20Fund rank 26/100 · Data gapFallback financials|
SA 17/F
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $3.7M · quality 44.3/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 17/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

17/100

F

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists. ROE is -21.7%, below the 5% threshold
Thesis & Journal · 8217.HKLocal privado en este navegador · Ju Fu Tang Biotech Holdings Co., Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$60M

P/E

2.9x

↓

EV/EBITDA

N/A

•

ROE

-21.7%

↓

Gross Margin

2.7%

↓

Debt/Equity

0.44

↑
52-Week Range$0
$0$0

TradingView lightweight chart

8217.HK price, volumen y niveles de valoración

Último $0.200Periodo -99.6%
Fair value: $0.200

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-26.9%

FCF CAGR

—

FCF margin

-20.1%

FCF / Net income

1.23x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $36.2M · net income $-5.9M · FCF $-7.3M

2022-FY → 2025-FY

Gross margin

2.7%+1.6% pts

Operating margin

-20.8%-10.5% pts

Net margin

-16.3%+5.4% pts

FCF margin

-20.1%+1.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$36.2M$36.2M$35.1M$104.6M$92.8M
Net Income$-5.9M$-5.9M$-17.4M$-10.0M$-20.1M
EBITDA$-5.1M$-5.1M$-16.6M$-9.1M$-19.1M
EPS-0.02-0.02-0.06-0.03-0.10
Gross Margin2.7%2.7%5.3%-2.8%1.1%
Operating Margin-20.8%-20.8%-16.2%-7.8%-10.3%
Net Margin-16.3%-16.3%-49.6%-9.5%-21.7%
Balance Sheet
Debt/Equity0.440.440.360.240.20
Current Ratio1.971.97———
Cash Flow
Free Cash Flow$-7.3M$-7.3M$3.7M$32.2M$-19.5M
Returns
ROE-21.7%-21.7%-52.6%-19.7%-33.3%
Valuation
P/E2.862.86———
P/B2.222.220.860.670.56
Growth & Yield
Revenue Growth3.0%3.0%-66.4%12.8%—
EPS Growth66.3%66.3%-75.2%67.1%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -11.9%

Total return

-11.9%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.06 → -0.02

Residual

-11.9%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-11.9%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.